Search Results

You are looking at 1 - 10 of 38 items for :

  • "anal cancer" x
Clear All
Full access

Yuefeng Wang, Xinhua Yu, Nan Zhao, Jiajing Wang, Chi Lin, Enrique W. Izaguirre, Michael Farmer, Gary Tian, Bradley Somer, Nilesh Dubal, David L. Schwartz, Matthew T. Ballo and Noam A. VanderWalde

The standard of care for locally advanced anal cancer is definitive pelvic chemoradiotherapy (CRT). 1 – 5 In the metastatic setting, chemotherapy (cisplatin/5-FU, carboplatin/paclitaxel, or FOLFOX) is considered the standard of care, and the

Full access

Yixing Jiang, Heath Mackley, Hua Cheng and Jaffer A. Ajani

anal cancer. However, treatment failure is frequent in patients with bulky primary tumors and regional lymphadenopathy. To improve the efficacy of chemoradiation, several approaches have been investigated, including changing mitomycin-based chemotherapy

Full access

Joseph M. Pepek, Christopher G. Willett and Brian G. Czito

Techniques for the treatment of anal cancer have developed in parallel with technologic advances in radiation therapy (RT). Combined chemotherapy and RT has replaced radical surgical resection as the cornerstone of treatment for anal malignancies

Full access

Van K. Morris and Cathy Eng

) is the first randomized phase II prospective study to compare 2 chemotherapy doublets, 5-FU/cisplatin versus carboplatin/paclitaxel, in patients with treatment-naïve metastatic anal cancer; results are expected to be reported in 2018. Because there

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass

estimated 8,580 new cases (2,960 men and 5,620 women) of anal cancer involving the anus, anal canal, or anorectum will occur in the United States in 2018, accounting for approximately 2.7% of digestive system cancers. 1 It has been estimated that 1

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Jordan D. Berlin, J. Michael Berry, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric Rohren, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small Jr., Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

recommendation is based on any level of evidence but reflects major disagreement. Overview An estimated 5290 new cases (2100 men and 3190 women) of anal cancer (involving the anus, anal canal, or anorectum) will occur in the United States in 2009

Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer and Deborah A. Freedman-Cass

(eg, smoking, heavy alcohol consumption) likely plays a role. 19 – 23 The proportions of each major cancer type among total US incident cancer cases in PLWH in 2010 were 13 : NHL, 21%; KS, 12%; lung cancer, 11%; anal cancer, 10%; prostate cancer, 7

Full access

Adam J. Kole, John M. Stahl, Henry S. Park, Sajid A. Khan and Kimberly L. Johung

Background Anal cancer constitutes 2% to 3% of gastrointestinal malignancies, with approximately 8,000 new cases estimated for 2016 in the United States. 1 Currently, concurrent chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and mitomycin

Full access

Rachel A. Bender Ignacio, Lilie L. Lin, Lakshmi Rajdev and Elizabeth Chiao

-negative populations, such as Kaposi sarcoma (KS) or anal cancer. This review summarizes and highlights current HIVAM clinical trials, with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors (ICIs

Full access

An estimated 3,900 new cases of anal canal cancer will occur in 2002, accounting for approximately 1.6% of digestive system cancers in the United States. NCCN clinical practice guidelines for managing anal cancer discuss the complete management of this disease, from clinical presentation through diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance.

For the most recent version of the guidelines, please visit NCCN.org